Ocular Therapeutix (NSDQ:OCUL) said today that it landed a licensing deal with Regeneron (NSDQ:REGN) to develop a sustained-release version of Regeneron’s aflibercept (Eylea), a therapy for wet age-related macular degeneration. The deal will cost Regeneron $10 million up front, and in total could cost the Tarrytown, N.Y.-based biotech $315 million if regulatory and commercialization milestones are met. The terms […]
Optical/Ophthalmic
Ocular therapeutics company Novaliq names new CEO
Novaliq GmbH said yesterday that it named Christian Roesky as its new CEO, replacing co-founder Bernhard Günther, who will take on a new role as chief innovation officer. The Heidelberg, Germany-based company focuses on renovating poorly soluble drugs into effective ocular therapeutics. Its CE-marked product, NovaTears, was developed from its proprietary EyeSol technology. With its […]
Oculis raises unspecified amount in Series B for drug-device eye disease combo
Ophthalmalogical developer Oculis said today it closed a Series A round of financing to support its solubilizing nanoparticle drug delivery platform, currently being designed to deliver drugs to treat diabetic macular edema. The company did not disclose the amount raised in the round. The SNP platform is designed to “solve the limitations of available eye-drop […]
